$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

$achv Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000156459017002109 Filed on February 23, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2016
Revenue	$0.00	$0.00	$5.060M
YoY Change	-100.0%	-100.0%	-72.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.530M	$2.300M	$8.930M
YoY Change	10.0%	-21.23%	-24.39%
% of Gross Profit
Research & Development	$61.00K	$80.00K	$286.0K
YoY Change	-6.15%	-98.79%	-98.86%
% of Gross Profit
Depreciation & Amortization	$93.00K	$40.00K	$190.0K
YoY Change	66.07%	-33.33%	-22.13%
% of Gross Profit
Operating Expenses	$61.00K	$80.00K	$286.0K
YoY Change	-99.17%	-98.79%	-99.23%
Operating Profit
YoY Change
Interest Expense	$30.00K	$40.00K	$200.0K
YoY Change	-40.0%	33.33%	66.67%
% of Operating Profit
Other Income/Expense, Net	-$8.000K	-$4.000K	-$24.00K
YoY Change	33.33%	-100.23%	-101.31%
Pretax Income	-$329.0K	-$5.840M	-$1.738M
YoY Change	-91.13%	239.53%	-89.65%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$205.0K	-$486.0K	-$1.234M
YoY Change	-15.29%	-71.78%	49.03%
Net Earnings / Revenue			-24.39%
Basic Earnings Per Share
Diluted Earnings Per Share	-$327.0M	-$584.0M	-$2.013B
COMMON SHARES
Basic Shares Outstanding	30.09M	30.02M
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$784.0K	$10.25M	$25.46M
YoY Change	-98.3%	-51.08%	-53.87%
Cash & Equivalents	$24.00K	$15.00K	$11.93M
Short-Term Investments	$760.0K	$10.23M	$11.73M
Other Short-Term Assets	$800.0K	$1.000M	$950.0K
YoY Change	243.35%	7042.86%	-52.26%
Inventory
Prepaid Expenses	$765.0K	$3.000K
Receivables	$237.0K	$478.0K	$480.0K
Other Receivables	$0.00	$0.00	$30.00K
Total Short-Term Assets	$17.45M	$18.00K	$26.93M
YoY Change	-63.63%	-99.97%	-53.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$166.0K	$300.0K	$260.0K
YoY Change	-69.6%	-50.0%	-56.67%
Goodwill		$1.034M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$300.0K	$290.0K
YoY Change	-65.79%	0.0%	-6.45%
Total Long-Term Assets	$451.0K	$3.789M	$540.0K
YoY Change	-47.31%	320.07%	-40.66%
TOTAL ASSETS
Total Short-Term Assets	$17.45M	$18.00K	$26.93M
Total Long-Term Assets	$451.0K	$3.789M	$540.0K
Total Assets	$17.90M	$3.807M	$27.47M
YoY Change	-63.34%	-93.46%	-52.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$359.0K	$95.00K	$2.120M
YoY Change	-39.36%	-92.69%	58.21%
Accrued Expenses	$1.400M	$6.000M	$6.050M
YoY Change	-86.14%	-49.58%	-49.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$60.00K
YoY Change	0.0%	0.0%	20.0%
Total Short-Term Liabilities	$1.980M	$3.073M	$8.460M
YoY Change	-86.34%	-85.13%	-59.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$50.00K
YoY Change	-100.0%	-100.0%	-54.55%
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$50.00K
YoY Change	-100.0%	-100.0%	-54.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.980M	$3.073M	$8.460M
Total Long-Term Liabilities	$0.00	$0.00	$50.00K
Total Liabilities	$2.012M	$3.197M	$8.500M
YoY Change	-86.22%	-84.61%	-59.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$200.2M	-$2.062M
YoY Change		-98.83%
Common Stock	$213.5M	$2.696M
YoY Change		-98.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.89M	$610.0K	$18.97M
YoY Change
Total Liabilities & Shareholders Equity	$17.90M	$3.807M	$27.47M
YoY Change	-63.31%	-93.46%	-52.81%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$205.0K	-$486.0K	-$1.234M
YoY Change	-15.29%	-71.78%	49.03%
Depreciation, Depletion And Amortization	$93.00K	$40.00K	$190.0K
YoY Change	66.07%	-33.33%	-22.13%
Cash From Operating Activities	-$9.000M	-$6.980M	-$202.0K
YoY Change	-0.99%	-34.64%	-97.78%
INVESTING ACTIVITIES
Capital Expenditures	$1.000K	-$10.00K	$46.00K
YoY Change		-85.71%	-87.6%
Acquisitions
YoY Change
Other Investing Activities	$9.470M	$10.42M	$10.65M
YoY Change	-250.08%	305.45%	-722.81%
Cash From Investing Activities	$9.470M	$10.42M	$10.61M
YoY Change	-250.08%	316.8%	-610.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-20.00K	0.000	150.0K
YoY Change		-100.0%	-99.15%
NET CHANGE
Cash From Operating Activities	-9.000M	-6.980M	-202.0K
Cash From Investing Activities	9.470M	10.42M	10.61M
Cash From Financing Activities	-20.00K	0.000	150.0K
Net Change In Cash	9.000K	3.440M	-52.00K
YoY Change	-100.06%	-142.11%	-185.25%
FREE CASH FLOW
Cash From Operating Activities	-$9.000M	-$6.980M	-$202.0K
Capital Expenditures	$1.000K	-$10.00K	$46.00K
Free Cash Flow	-$9.001M	-$6.970M	-$248.0K
YoY Change		-34.31%	-97.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26147344
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.45
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18098799
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29949432
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20121000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16791000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26261000
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30086106
CY2016Q2	dei	Entity Public Float EntityPublicFloat	29650858
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34310000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	26927000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	272000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5040000
CY2015	us-gaap	Reimbursement Revenue ReimbursementRevenue	18160000
CY2014	us-gaap	Reimbursement Revenue ReimbursementRevenue	27116000
CY2016	ogxi	Gain On Reversal Of Lease Termination Liability GainOnReversalOfLeaseTerminationLiability	1250000
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	202000
CY2014	ogxi	Warrant Issuance Costs WarrantIssuanceCosts	531000
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	29000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	37211000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3860000
CY2014	ogxi	Stock Issued During Period Value Performance Restricted Stock Unit Settlements Withheld And Retired To Treasury StockIssuedDuringPeriodValuePerformanceRestrictedStockUnitSettlementsWithheldAndRetiredToTreasury	29000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	34059000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2328000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000
CY2015	ogxi	Stock Issued During Period Value Performance Restricted Stock Unit Settlements Withheld And Retired To Treasury StockIssuedDuringPeriodValuePerformanceRestrictedStockUnitSettlementsWithheldAndRetiredToTreasury	52000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1649000
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-2000
CY2015	us-gaap	Depreciation Depreciation	244000
CY2014	us-gaap	Depreciation Depreciation	223000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2328000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	3860000
CY2014	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	3517000
CY2015	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-2000
CY2014	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-105000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5662000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2981000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1167000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3944000
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1271000
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-67000
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-222000
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	363000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3714000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2178000
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-66000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-372000
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	21000
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-63000
CY2014	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-785000
CY2014	ogxi	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	84000
CY2015	ogxi	Increase Decrease In Lease Termination Fee IncreaseDecreaseInLeaseTerminationFee	-2000000
CY2014	ogxi	Increase Decrease In Lease Termination Fee IncreaseDecreaseInLeaseTerminationFee	3250000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5040000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5040000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-29683000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9101000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17308000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	47158000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	10608000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19077000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6413000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27897000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2000
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	52000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22372000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17591000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	25247000
CY2016	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	36504000
CY2015	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	24368000
CY2014	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	19446000
CY2015	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1003000
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	21659000
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	24894000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	371000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2077000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	5366000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13304000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14593000
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	218000
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and notes thereto. Actual results could differ from these estimates. Estimates and assumptions principally relate to estimates of the fair value of our warrant liability, the initial fair value and forfeiture rates of stock options issued to employees and consultants, the estimated compensation cost on performance restricted stock unit awards and clinical trial and manufacturing accruals, estimated useful lives of property, plant and equipment and estimates and assumptions in contingent liabilities. </p></div>
CY2015	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	13000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	67000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	14000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	452000
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3000
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	25500000
CY2016	ogxi	Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent	P3M
CY2016	ogxi	Description Of Maturity Period Of Financial Instruments To Be Considered As Short Term Investment DescriptionOfMaturityPeriodOfFinancialInstrumentsToBeConsideredAsShortTermInvestment	Greater than three months and less than one year
CY2016	ogxi	Amount To Be Spent In Direct And Indirect Development Costs Under Agreement AmountToBeSpentInDirectAndIndirectDevelopmentCostsUnderAgreement	30000000
CY2009	us-gaap	Licenses Revenue LicensesRevenue	22000000
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2016	ogxi	Average Period To Maturity For Portfolio Of Cash And Marketable Securities AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities	P45D
CY2015	ogxi	Average Period To Maturity For Portfolio Of Cash And Marketable Securities AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities	P61D
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	232000
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1105000
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	873000
CY2016Q4	us-gaap	Cash Cash	1800000
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10231000
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10230000
CY2015Q4	us-gaap	Cash Cash	14034000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	272000
CY2015Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	20885000
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	20876000
CY2016	ogxi	Maximum Maturity Period Of Cash And Cash Equivalents MaximumMaturityPeriodOfCashAndCashEquivalents	P90D
CY2016	ogxi	Maximum Maturity Period Of Short Term Investments MaximumMaturityPeriodOfShortTermInvestments	P1Y
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1707000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1883000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1449000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1281000
CY2016Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	202000
CY2015Q1	ogxi	Additional Contingent Liability Early Termination Of Lease Agreement AdditionalContingentLiabilityEarlyTerminationOfLeaseAgreement	1300000
CY2016	ogxi	Period Of Not Utilizing Prepaid Amounts Related To Clinical Trials PeriodOfNotUtilizingPrepaidAmountsRelatedToClinicalTrials	P12M
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	ogxi	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2015	ogxi	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2014	ogxi	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	158391000
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	151900000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	6844000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	5712000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	8922000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	84358000
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	9000
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-972000
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-689000
CY2016	ogxi	Income Tax Reconciliation Change In Benefit Of Operating Losses IncomeTaxReconciliationChangeInBenefitOfOperatingLosses	-196000
CY2015	ogxi	Income Tax Reconciliation Change In Benefit Of Operating Losses IncomeTaxReconciliationChangeInBenefitOfOperatingLosses	32000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment	-252000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment	-297000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Investment IncomeTaxReconciliationTaxCreditsInvestment	-357000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6203000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5114000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7854000
CY2016	ogxi	Income Tax Reconciliation Book To Tax Return Adjustments IncomeTaxReconciliationBookToTaxReturnAdjustments	205000
CY2015	ogxi	Income Tax Reconciliation Book To Tax Return Adjustments IncomeTaxReconciliationBookToTaxReturnAdjustments	-265000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016Q4	ogxi	Non Capital Gain Loss Carryforwards Amount NonCapitalGainLossCarryforwardsAmount	115950000
CY2016	ogxi	Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures	14600000
CY2016	ogxi	Tax Credit Carryforward Expiration Year Range Start TaxCreditCarryforwardExpirationYearRangeStart	2018
CY2016	ogxi	Tax Credit Carryforward Expiration Year Range End TaxCreditCarryforwardExpirationYearRangeEnd	2036
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6483000
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6308000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77746000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7969000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7484000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3743000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3448000
CY2016Q4	ogxi	Deferred Tax Assets Liabilities Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsLiabilitiesTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	624000
CY2015Q4	ogxi	Deferred Tax Assets Liabilities Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsLiabilitiesTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	474000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	112000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1627000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103289000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	97087000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	103289000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	97087000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2055000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2039000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2007000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	32000
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2000000
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000
CY2014Q3	ogxi	Net Proceeds Received From Offering After Deducting Underwriting Discounts And Offering Expenses NetProceedsReceivedFromOfferingAfterDeductingUnderwritingDiscountsAndOfferingExpenses	22400000
CY2014Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	24000000
CY2014Q3	ogxi	Warrant Issuance Costs WarrantIssuanceCosts	1600000
CY2016Q4	us-gaap	Costs And Expenses CostsAndExpenses	6013000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	675000
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	170000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-3690000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-5843000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.91
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5359
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10000
CY2016	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	217296
CY2015	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	269401
CY2014	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	203148
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0151
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0183
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.63
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.82
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.53
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.10
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.52
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1007491
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	382097
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	12169
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	84000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.39
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.97
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	18.93
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.00
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.14
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.55
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.96
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.69
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.37
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.78
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.86
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.00
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1378805
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.62
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1024529
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	10.54
CY2016	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y6M29D
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	600000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2787000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	51100000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2016	ogxi	Number Of Warrants Exercised NumberOfWarrantsExercised	0
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5800000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7000000
CY2016Q4	us-gaap	Contractual Obligation ContractualObligation	492000
CY2016Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	372000
CY2016Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	107000
CY2016Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	9000
CY2016Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	4000
CY2016	ogxi	Expiration Of Operating Lease Agreement ExpirationOfOperatingLeaseAgreement	2016-09
CY2015Q3	ogxi	Expansion Of Rental Space Notice Provided ExpansionOfRentalSpaceNoticeProvided	2245
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2800000
CY2016Q4	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	0
CY2016	ogxi	Indemnification Expense IndemnificationExpense	0
CY2016Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	11
CY2016Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.27
CY2016Q1	us-gaap	Severance Costs1 SeveranceCosts1	400000
CY2016Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	14
CY2016Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.48
CY2016	us-gaap	Severance Costs1 SeveranceCosts1	1100000
CY2016Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	5
CY2016Q4	us-gaap	Severance Costs1 SeveranceCosts1	700000
CY2016Q4	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	2206000
CY2016	us-gaap	Payments For Restructuring PaymentsForRestructuring	708000
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	1498000
CY2016Q1	us-gaap	Reimbursement Revenue ReimbursementRevenue	2940000
CY2016Q2	us-gaap	Reimbursement Revenue ReimbursementRevenue	2122000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4642000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4662000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3782000
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1702000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2299000
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2475000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1864000
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2295000
CY2016Q1	ogxi	Restructuring Costs Recovery RestructuringCostsRecovery	431000
CY2016Q2	ogxi	Restructuring Costs Recovery RestructuringCostsRecovery	-8000
CY2016Q3	ogxi	Restructuring Costs Recovery RestructuringCostsRecovery	-31000
CY2016Q4	ogxi	Restructuring Costs Recovery RestructuringCostsRecovery	1814000
CY2016Q3	ogxi	Gain On Reversal Of Lease Termination Liability GainOnReversalOfLeaseTerminationLiability	1250000
CY2016Q2	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1375000
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	7372000
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	8504000
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	4365000
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	725000
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-507000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3707000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-6889000
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2015Q1	us-gaap	Reimbursement Revenue ReimbursementRevenue	1374000
CY2015Q2	us-gaap	Reimbursement Revenue ReimbursementRevenue	4025000
CY2015Q3	us-gaap	Reimbursement Revenue ReimbursementRevenue	6737000
CY2015Q4	us-gaap	Reimbursement Revenue ReimbursementRevenue	6024000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3673000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6545000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8303000
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6587000
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2698000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3067000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3125000
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2915000
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	6371000
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	9612000
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	11428000
CY2015Q4	us-gaap	Costs And Expenses CostsAndExpenses	9502000
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	480000
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-423000
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	141000
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1756000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4517000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6010000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4550000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-1722000
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.20
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.26
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.16
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.06

Files In Submission

Name	View Source	Status
0001564590-17-002109-index-headers.html	Edgar Link	pending
0001564590-17-002109-index.html	Edgar Link	pending
0001564590-17-002109.txt	Edgar Link	pending
0001564590-17-002109-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g201702222044204696995.jpg	Edgar Link	pending
ogxi-10k_20161231.htm	Edgar Link	pending
ogxi-20161231.xml	Edgar Link	completed
ogxi-20161231.xsd	Edgar Link	pending
ogxi-20161231_cal.xml	Edgar Link	unprocessable
ogxi-20161231_def.xml	Edgar Link	unprocessable
ogxi-20161231_lab.xml	Edgar Link	unprocessable
ogxi-20161231_pre.xml	Edgar Link	unprocessable
ogxi-ex211_9.htm	Edgar Link	pending
ogxi-ex231_666.htm	Edgar Link	pending
ogxi-ex311_11.htm	Edgar Link	pending
ogxi-ex312_10.htm	Edgar Link	pending
ogxi-ex321_6.htm	Edgar Link	pending
ogxi-ex322_8.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

2017 Q1 Form 10-K Financial Statement

#000156459017002109 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV ACHIEVE LIFE SCIENCES, INC. Stock $achv

2017 Q1 Form 10-K Financial Statement

#000156459017002109 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv